Abstract
Until more effective and especially disease-modifying treatments for Alzheimer’s disease (AD) are available, the therapeutic arsenal consists of cholinesterase inhibitors for mild to moderate dementia and memantine for moderate to severe dementia. Health economic data make an important contribution to the planning of healthcare services and the estimation of the cost of drug reimbursement. As such, for cholinesterase inhibitors it is claimed that the direct cost of the drug itself is eclipsed by the cost savings associated with delaying institutionalisation or delaying the time of progression into a more severe disease state. The present manuscript reviews several factors contributing to the costs of AD, gives an overview of available studies claiming the cost-effectiveness of current AD treatments, highlights strengths and weaknesses of the aforementioned studies, and discusses the impact of (early) identification and treatment of AD. It is concluded that there still is a need for long-term follow-up data from prospective cohort studies before the cost-effectiveness of cholinesterase inhibitors for AD can be confirmed.
Similar content being viewed by others
References
Burns A, Iliffe S (2009) Alzheimer’s disease. BMJ 338:b158
Querfurth HW, Laferla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344
Scuvee-Moreau J, Kurz X, Dresse A (2002) The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES). Acta Neurol Belg 102:104–113
Qiu C, Kivipelto M, Von SE (2009) Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111–128
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031
Jönsson L, Berr C (2005) Cost of dementia in Europe. Eur J Neurol 12(Suppl 1):50–53
Wimo A, Jonsson L, Gustavsson A et al (2010) The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry
Wimo A, Winblad B, Jonsson L (2007) An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 3:81–91
Lowin A, Knapp M, McCrone P (2001) Alzheimer’s disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry 16:1143–1148
Sousa RM, Ferri CP, Acosta D et al (2009) Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey. Lancet 374:1821–1830
Wimo A, Winblad B, Jonsson L (2010) The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6:98–103
Jonsson L, Eriksdotter JM, Kilander L et al (2006) Determinants of costs of care for patients with Alzheimer’s disease. Int J Geriatr Psychiatry 21:449–459
Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F (2004) Assessing the health and economic impact of galantamine treatment in patients with Alzheimer’s disease in the health care systems of different countries. Drugs Aging 21:677–686
World Health Organization The global burden of disease: 2004 update. Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html. Last accessed: October 2011
Ballard C, Sorensen S, Sharp S (2007) Pharmacological therapy for people with Alzheimer’s disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. J Alzheimers Dis 12:53–59
Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T (2004) Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin 20:1221–1225
Fagnani F, Lafuma A, Pechevis M et al (2004) Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement Geriatr Cogn Disord 17:5–13
Feldman H, Gauthier S, Hecker J et al (2004) Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63:644–650
Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B (2002) Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 20:629–637
Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 51:937–944
Getsios D, Blume S, Ishak KJ, Maclaine GD (2010) Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 28:411–427
Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA (2000) Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigmine. Pharmacoeconomics 17:351–360
Marin D, Amaya K, Casciano R et al (2003) Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int Psychogeriatr 15:385–398
Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G (2003) Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United States. Clin Ther 25:1806–1825
O’Brien BJ, Goeree R, Hux M et al (1999) Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 47:570–578
Ward A, Caro JJ, Getsios D, Ishak K, O’Brien J, Bullock R (2003) Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 18:740–747
Courtney C, Farrell D, Gray R et al (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363:2105–2115
Holmes C, Burns A, Passmore P, Forsyth D, Wilkinson D (2004) AD2000: design and conclusions. Lancet 364:1213–1214
Lopez OL, Becker JT, Wahed AS et al (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 80:600–607
Loveman E, Green C, Kirby J et al (2006) The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess 10:iii–xi, 1
Weycker D, Taneja C, Edelsberg J et al (2007) Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr Med Res Opin 23:1187–1197
Green C (2007) Modelling disease progression in Alzheimer’s disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 25:735–750
Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A (2005) Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics 23:1271–1282
Stewart A, Phillips R, Dempsey G (1998) Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int J Geriatr Psychiatry 13:445–453
Oremus M (2008) Systematic review of economic evaluations of Alzheimer’s disease medications. Expert Rev Pharmacoecon Outcomes Res 8:273–289
Waldemar G, Phung KT, Burns A et al (2007) Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 22:47–54
Hill J, Fillit H, Thomas SK, Chang S (2006) Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer’s disease and other dementias. Pharmacoeconomics 24:265–280
Small GW, McDonnell DD, Brooks RL, Papadopoulos G (2002) The impact of symptom severity on the cost of Alzheimer’s disease. J Am Geriatr Soc 50:321–327
Weimer DL, Sager MA (2009) Early identification and treatment of Alzheimer’s disease: social and fiscal outcomes. Alzheimers Dement 5:215–226
Ikeda S, Yamada Y, Ikegami N (2002) Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dement Geriatr Cogn Disord 13:33–39
Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B (1999) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 21:1230–1240
Wimo A, Winblad B, Engedal K et al (2003) An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15:44–54
Lu S, Hill J, Fillit H (2005) Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer’s disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Am J Geriatr Pharmacother 3:92–102
Acknowledgements
The present study was initiated and funded by Pfizer Ltd. The views expressed in this article are those of the author.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Versijpt, J. Pharmacoeconomics of Alzheimer’s disease (AD) treatment with cholinesterase inhibitors. Acta Neurol Belg 112, 141–145 (2012). https://doi.org/10.1007/s13760-012-0062-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-012-0062-9